Key updates and interpretations of the 2026 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Report

doi:10.19983/j.issn.2096-8493.20250209

Journal of Tuberculosis and Lung Disease ›› 2026, Vol. 7 ›› Issue (2): 152-155.doi: 10.19983/j.issn.2096-8493.20250209

• Interpretation of Standards • Previous Articles

Key updates and interpretations of the 2026 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Report

Liu Yidian¹, Yuan Xuefang², Long Yingjiao¹^,³^,⁴^,⁵()

¹ Department of Pulmonary and Critical Care Medicine, the Second Xiangya Hospital, Central South University, Changsha 410011, China
² Department of Respiratory Medicine, Hunan Want Want Hospital, Changsha 410009, China
³ Research Unit of Respiratory Disease, Central South University, Changsha 410011, China
⁴ Clinical Medical Research Center for Pulmonary and Critical Care Medicine in Hunan Province, Changsha 410011, China
⁵ Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha 410011, China

Received:2025-12-25 Online:2026-04-20 Published:2026-04-13
Contact: Long Yingjiao E-mail:longyingjiao@163.com
Supported by:
Natural Science Foundation of Hunan Province(2024JJ5487);National Major Scientific and Technological Special Project for Cancer, Cardiovascular and Cerebrovascular, Respiratory, and Metabolic Disease Prevention and Treatment Research(2025ZD0548800);National Key Clinical Specialty Construction Projects of China(Z2023164)

Abstract

Abstract:

Chronic obstructive pulmonary disease (COPD) is a common preventable and treatable chronic airway disease. The updated Global Initiative for Chronic Obstructive Lung Disease 2026 (GOLD 2026) focuses on early screening and dynamic precise assessment, aligning more closely with clinical practice. For the first time, it includes a dedicated chapter on artificial intelligence empowerment, providing guidance for the implementation of whole-life-cycle management of COPD. The author herein reviews the key updates in GOLD 2026, aiming to facilitate a better understanding of the rationale and direction behind the guideline revisions, thereby informing clinical practice and future research directions.

Key words: Chronic obstructive pulmonary disease, Review, Treatment, Benchmarking, Comment

CLC Number:

R563.9

Liu Yidian, Yuan Xuefang, Long Yingjiao. Key updates and interpretations of the 2026 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Report[J]. Journal of Tuberculosis and Lung Disease , 2026, 7(2): 152-155. doi: 10.19983/j.issn.2096-8493.20250209

References 16

[1]	Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet, 2018, 391(10131):1706-1717. doi:10.1016/S0140-6736(18)30841-9. pmid: 29650248
[2]	Tisi S, Dickson JL, Horst C, et al. Detection of COPD in the SUMMIT Study lung cancer screening cohort using symptoms and spirometry. Eur Respir J, 2022, 60(6):2200795. doi:10.1183/13993003.00795-2022.
[3]	Bradley C, Boland A, Clarke L, et al. Diagnosis and treatment outcomes from prebronchodilator spirometry performed alongside lung cancer screening in a Lung Health Check programme. Thorax, 2023, 78(6):543-550. doi:10.1136/thorax-2022-219683.
[4]	Liu M, Yin D, Wang Y, et al. Comparing the Performance of Two Screening Questionnaires for Chronic Obstructive Pulmonary Disease in the Chinese General Population. Int J Chron Obstruct Pulmon Dis, 2023, 18:541-552. doi:10.2147/COPD.S403603.
[5]	Yang T, Cai B, Cao B, et al. Exacerbation in patients with stable COPD in China: analysis of a prospective, 52-week, nationwide, observational cohort study (REAL). Ther Adv Respir Dis, 2023, 17: 17534666231167353. doi:10.1177/17534666231167353.
[6]	Whittaker H, Rubino A, Müllerová H, et al. Frequency and Severity of Exacerbations of COPD Associated with Future Risk of Exacerbations and Mortality: A UK Routine Health Care Data Study. Int J Chron Obstruct Pulmon Dis, 2022, 17:427-437. doi:10.2147/COPD.S346591.
[7]	Rhodes K, Patel D, Duong ML, et al. Future exacerbations and mortality rates among patients experiencing COPD exacerbations: a meta-analysis of results from the EXACOS/AVOIDEX programme. BMJ Open, 2025, 15(7):e097006. doi:10.1136/bmjopen-2024-097006.
[8]	Cazzola M, Matera MG. Clinically important deterioration: a composite tool for managing patients with COPD. Respir Med, 2022, 205:107054. doi:10.1016/j.rmed.2022.107054.
[9]	Newsome SD, Binns C, Kaunzner UW, et al. No evidence of disease activity (NEDA) as a clinical assessment tool for multiple sclerosis: clinician and patient perspectives [Narrative Review]. Neurol Ther, 2023, 12(6):1909-1935. doi:10.1007/s40120-023-00549-7. pmid: 37819598
[10]	Deighton C, Rudolf M. How does rheumatoid arthritis need to be managed?. Clin Med (Lond), 2010, 10(2):151-153. doi:10.7861/clinmedicine.10-2-151.
[11]	Çolak Y, Afzal S, Marott JL, et al. Type-2 inflammation and lung function decline in chronic airway disease in the general population. Thorax, 2024, 79(4):349-358. doi:10.1136/thorax-2023-220972. pmid: 38195642
[12]	Ritchie AI, Donaldson GC, Hoffman EA, et al. Structural Predictors of Lung Function Decline in Young Smokers with Normal Spirometry. Am J Respir Crit Care Med, 2024, 209(10):1208-1218. doi:10.1164/rccm.202307-1203OC.
[13]	Topole E, Biondaro S, Montagna I, et al. Artificial intelligence based software facilitates spirometry quality control in asthma and COPD clinical trials. ERJ Open Res, 2023, 9(1):00292-2022. doi:10.1183/23120541.00292-2022.
[14]	Wu Y, Xia S, Liang Z, et al. Artificial intelligence in COPD CT images: identification, staging, and quantitation. Respir Res, 2024, 25(1):319. doi:10.1186/s12931-024-02913-z.
[15]	Hasenstab KA, Yuan N, Retson T, et al. Automated CT staging of chronic obstructive pulmonary disease severity for predicting disease progression and mortality with a deep learning convolutional neural network. Radiol Cardiothorac Imaging, 2021, 3(2):e200477. doi:10.1148/ryct.2021200477.
[16]	Wu R, de Lara E, Liaqat D, et al. Feasibility of a wearable self-management application for patients with COPD at home: a pilot study. BMC Med Inform Decis Mak, 2024, 24(1):66. doi:10.1186/s12911-024-02461-y.

Key updates and interpretations of the 2026 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Report

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 16

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Yuan Jingsong, Chen Jingfang, Deng Guofang, Lin Yi, Meng Ting, Ma Mengting. Progress of research on the health literacy assessment tools for tuberculosis patients [J]. Journal of Tuberculosis and Lung Disease, 2026, 7(1): 120-124.
[2]	Zhang Yingkui, Zhang Guanxia, Yang Zijuan, Wang Xiuchuan. Cervical tuberculous lymphadenitis in a patient on maintenance hemodialysis: a case report and literature review [J]. Journal of Tuberculosis and Lung Disease, 2026, 7(1): 80-85.
[3]	Tian Xiaomei, He Xiaoxue, Lei Juan, Wang Xiaowei, Gu Jianjun. Analysis of treatment outcomes and influencing factors for bacteriologically positive pulmonary tuberculosis in Ningxia Hui Autonomous Region from 2019 to 2023 [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(6): 703-709.
[4]	Sha Xiaolan, Tian Xiaofu, Tian Xiaomei, Liu Tao, Lei Juan. Analysis of treatment outcome and its influencing factors of multidrug/rifampicin-resistant pulmonary tuberculosis patients in Ningxia Hui Autonomous Region from 2018 to 2022 [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(6): 710-716.
[5]	Liao Wenping, Zhang Liyi, Zhang Wen, Su Qian. Analysis of treatment outcomes and influencing factors among student pulmonary tuberculosis patients in Chongqing from 2020 to 2023 [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(6): 725-730.
[6]	Chinese Association of Integrative Medicine China Association of Chinese Medicine Chinese Medical Association. Diagnosis and treatment of the integrated Chinese and western medicine guidelines for drug-resistant pulmonary tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(5): 477-494.
[7]	An Yuan, Bai Yunlong, Zhao Qinglong, Jiang Xue, Pan Yan, Yang Fan. Analysis of characteristics and treatment outcomes of patients with rifampicin-resistant pulmonary tuberculosis in Jilin Province, 2018—2022 [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(5): 566-572.
[8]	Hou Wenjun, Tian Feifei, Zhang Shiyu, Zhang Yaowen, Dou Yamei, Xue Han, Cui Hongyan. Epidemiological characteristics and treatment outcomes of pulmonary tuberculosis patients with diabetes and hypertension in Daxing District, Beijing from 2022 to 2024 [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(5): 579-586.
[9]	Xie Xuping, Zeng Xiaogang, Li Fuping, Sun Nannan, Yu Limei, Jiang Qilong, Tang Wenshuai. Research progress on prognostic factors and comprehensive prevention and treatment strategies of tuberculous pericarditis [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(4): 464-471.
[10]	Qian Guilan, Wang Lin. Research progress on the caregiving burden of family members of patients with chronic obstructive pulmonary disease [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(3): 343-347.
[11]	Zheng Ling, Xia Binxue, Yang Haiyan, Cheng Yan, Xiong Hong. Advances in the application of virtual reality in respiratory training for patients with chronic obstructive pulmonary disease [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(3): 348-353.
[12]	Liu Jingyi, Hou Yue, Wu Jianlin. A brief discussion on the origin and current status of pulmonary ground glass nodules from the perspective of imaging [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(2): 121-124.
[13]	Jiang Qi, Ma Yiming, Chen Yan. Review of the 2025 Global Initiative for Chronic Obstructive Lung Disease (GOLD) updates: focusing on personalized treatment, comorbidity management, and vaccination [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(2): 125-127.
[14]	Chen Hua, Chen Pinru. 2025 Update interpretation of “T/CHATA-001-2025 non-tuberculous mycobacteria disease diagnosis” social organization standard [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(2): 135-142.
[15]	Yu Mingliu, Gong Beibei, Chen Yuehua, Lan Weien, Wei Haiming, Gan Lin, Chen Xianglan. Effectiveness of pulmonary rehabilitation combined with early mobilization program in patients with pulmonary tuberculosis receiving invasive mechanical ventilation [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(2): 217-224.